Senior insider sale
SVP, Comm & Medical Affairs at THERAVANCE BIOPHARMA, INC. — senior position signals high conviction
$300.0K
28K shares
What this filing means
FARNUM RHONDA plans to sell 28K shares of THERAVANCE BIOPHARMA, INC. valued at approximately $300.0K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/2/2025ACC: 0001950047-25-003658
Officer· SVP, Comm & Medical Affairs
Since Dec 2021
28K
Shares to sell
$300.0K
Approx. market value
24K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months4
Performance Shares
Not Applicable
2/20/2021
13.50KRestricted Stock
Not Applicable
2/20/2021
7.12KRestricted Stock
Not Applicable
8/20/2020
2.82KPerformance Shares
Not Applicable
2/20/2020
561.00Total acquired24K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/20/2021 | Performance Shares Not Applicable | 13.50K | — |
2/20/2021 | Restricted Stock Not Applicable | 7.12K | — |
8/20/2020 | Restricted Stock Not Applicable | 2.82K | — |
2/20/2020 | Performance Shares Not Applicable | 561.00 | — |
| Total | 24K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
4K
Market value
$36.0K
4/21/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
24K
Market value
$264.0K
6/2/2025
Total
Units
28K
Value
$300.0K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
4/21/2025 | 4K | $36.0K | — | Completed |
| Planned — Approximate Date | ||||
6/2/2025 | 24K | $264.0K | NASDAQ | Planned |
| Total | 28K | $300.0K | ||